期刊文献+

20例皮肤瘢痕癌中RAS蛋白表达及意义 被引量:3

下载PDF
导出
摘要 目的探讨皮肤瘢痕癌中RAS蛋白(H-ras/N-ras/K-ras)表达及意义。方法以20例皮肤瘢痕癌组织为研究对象,以10例正常皮肤表皮和16例瘢痕上皮为对照。采用免疫组化SP法分别检测H-ras、N-ras、K-ras蛋白的表达并结合图像分析,分别观测各组被检组织中所检各项指标的表达(平均光密度和阳性面积)。结果 (1)H-ras、N-ras、K-ras蛋白在正常皮肤表皮和瘢痕上皮中呈阴性或弱阳性,在瘢痕癌组织中呈强阳性,瘢痕癌组的表达(平均光密度和阳性面积)与正常皮肤组和瘢痕组相比,差异有统计学意义(P<0.05)。(2)K-ras蛋白阳性信号在正常皮肤表皮呈胞核表达,在瘢痕上皮中同时出现胞核和胞质表达,在瘢痕癌中呈胞质表达,出现自胞核向胞质移位表达。(3)瘢痕癌中不管是组织学类型还是细胞的分化,均显示分化越高RAS蛋白表达越强,分化越低RAS蛋白表达越弱,高分化组与低分化组相比,差异有统计学意义(P<0.05)。结论 H-ras、N-ras、K-ras 3种蛋白的高表达以及K-ras蛋白的移位表达可能与瘢痕癌的发生有关3,种蛋白的表达强度与肿瘤细胞的分化成熟度相一致。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2011年第11期1237-1239,共3页 Chinese Journal of Clinical and Experimental Pathology
基金 贵州省攻关项目(2010-3080)
  • 相关文献

参考文献10

  • 1Schubbert S, Shannon K, Bollag G. Hyperactive RAS in develop- mental disorders and cancer [ J]. Nat Rev Cancer, 2007,7 ( 4 ) :295 - 308.
  • 2Akslen L A, Angelini S, Straume O, et al. BRAF and NRAS mu- tations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival [ J ]. J Invest Dermatol, 2005,125 (2) :312 -7.
  • 3Tanikawa E, Mori O, Hachisuka H, Sasai Y. Expression of ras proto - oncogene related protein p21 in normal human skin and cutaneous tumours[J]. Aeta Histoehem, 1992,93(1) :282 -9.
  • 4Platz A, Jungnelius U, GrafstrSm E, et al. Glutathione transferase PI-1 expression in human melanoma metastases: correlation to N- RAS mutations and expression [ J ]. Acta Oncol, 1995,34 ( 6 ) :759 - 65.
  • 5甄时建,杨举伦.以ras信号通路为靶标的抗肿瘤治疗研究进展[J].临床与实验病理学杂志,2008,24(5):607-611. 被引量:7
  • 6Stites E C, Ravichandran K S. A systems perspective of ras signa- ling in cancer[J]. Clin Cancer Res, 2009,15(5) :1510 -3.
  • 7Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival[J]. J Cell Mol Med, 2005,9( 1 ) :59 - 71.
  • 8Neill G W, Ghali L R, Green J L, et al. Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Glil in basal cell carcinoma[ J]. Cancer Res, 2003,63 ( 15 ) :4692 - 7.
  • 9Goodwin J S, Drake K R, Rogers C, et al. Depalmitoylated RAS traffics to and from the Golgi complex via a nonvesicular pathway [J]. J Cell niol, 2005,170(2):261 -72.
  • 10Kikuchi A, Amagai M, Hayakawa K, et al. Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumours [ J ]. Br J Dermatol, 1990,123 ( 1 ) :49 - 58.

二级参考文献51

  • 1DeBono J S, Rowinsky E K. The ErbB receptor family: a therapeutic target for cancer [ J ]. Trends Mol Med,2002,8 (4 Suppl) : S19 -S26.
  • 2Herbst R S. ZD1839 : targeting the epidermal growth factor receptor in cancer therapy [ J ]. Expert Opin Investig Drugs, 2002,11 (6) :837 -849.
  • 3Hidalgo M, Siu L L, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [ J]. J Clin Oncol,2001,19 ( 13 ) :3267 - 3279.
  • 4Robert F, Ezekiel M P, Spencer S A, et al. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer [ J ]. J Clin Oncol,2001,19 ( 13 ) : 3234 - 3243.
  • 5Swog S. Phase Ⅲ randomized study of gemcitabine with versus without cetuximab as first-line therapy in patients with locally advanced unrestable or metastatic adenocarcinoma of the pancreas [ J ]. Clin Adv Hematol Oncol,2004,2 (4) :201 - 252.
  • 6Graeven U, Kremer B, Sudhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer [J]. Br J Cancer,2006,94(9) :1293 - 1299.
  • 7Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [ J]. N Engl J Med, 2001,344 ( 11 ) :783 -792.
  • 8Alvarez R D, Barnes M N, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain anti- body-encoding adenovirus ( AD21 ) : a phase I trial [ J ]. Clin Cancer Res,2000,6 (8) :3081 - 3087.
  • 9Deshane J, Siegal GP, Wang M, et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy [ J ]. Gynecol Oncol, 1997,64 ( 3 ) : 378 - 385.
  • 10Mamot C, Drummond D C, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRⅧ-overexpressing tumor cells[J]. Cancer Res,2003,63(12) :3154 -3161.

共引文献6

同被引文献53

  • 1袁力勇,戴体俊,苏珍,葛源.跳台实验训练后小鼠自然遗忘时间的观察[J].徐州医学院学报,2007,27(2):84-85. 被引量:15
  • 2Pons M, Quintanilla M. Molecular biology of malignant melanoma and other cutaneous tumors[ J]. Clin Transl Oncol, 2006,8 (7) : 466 - 74.
  • 3Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin : molecular bases for EG- FR-targeted therapy [ J ]. Pathol Res Proct, 2011,207 ( 6 ) : 337 - 42.
  • 4Schubbert S, Shannon K, Bollag G. Hyperactive Ras in develop- mental disorders and cancer[J]. Nature, 2007,7 (4) :295 -308.
  • 5Barauit L, Veyrie N, Jooste V, et al. Mutations in the RAS- MAPK, PI ( 3 ) K signaling network correlate with poor survival in a population-based series of colon cancer[ J]. Int J Cancer, 2008, 122 (10) :2255 - 9.
  • 6Wang J Y, Wilcoxen K M, Nomoto K, et al. Recent advances of MEK inhibitors and their clinical progress [ J ]. Curt Top Med Chem, 2007,7 ( 14 ) : 1364 - 78.
  • 7Repasky G A, Chenette E J, Der C J. Renewing the conspiracy theory debate : does Raf function alone to mediate Ras oncogenesis [ J] ? Trends Cell Biol, 2004,14( 11 ) :639 -47.
  • 8Mccubrey J A, Steelman L S, Chappell W H, et al. Roles of the Raf/MEK/ERK pathway in cell growth malignant transformation and drug resistance [ J ]. Bioehim Biophys Acta, 2007,1773 (8) : 1263 - 84.
  • 9Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity [ J]. J Cell Sci, 2005,118 ( 14 ) : 2997 - 3002.
  • 10Shields D J, Murphy E A, Desgrosellier J S, et al. Oncogenic Ras/Src cooperativity in pancreatic neoplasia [ J ]. Oncogene, 2011,30(18) :2123 -34.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部